Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6
Semaglutide treatment improved cardiorenal outcomes versus placebo in people with T2D, regardless of prior CVD and baseline BMI. This improvement was observed even when accounting for changes in BW, indicating direct effects of semaglutide on the cardiorenal system. This analysis supports the broad efficacy of semaglutide in a diverse T2D population.
Authors
- Tina Vilsbøll (ORCID: https://orcid.org/0000-0002-0456-6787)
- Mansoor Husain (ORCID: https://orcid.org/0000-0002-3740-6739)
- Yang Li (ORCID: https://orcid.org/0000-0002-0088-1544)
- Junbo Ge (ORCID: https://orcid.org/0000-0002-9360-7332)
- Wenyan Liu (ORCID: https://orcid.org/0000-0002-9312-1295)
- Jingmin Zhou (ORCID: https://orcid.org/0000-0003-0195-2727)
- Zewei Shen
Institutions
- Steno Diabetes Centers (DK)
- Fudan University (CN)
- Ted Rogers Centre for Heart Research (CA)
- Zhongshan Hospital (CN)
- Novo Nordisk (Italy) (IT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1111/dom.16621
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Novo Nordisk